Impact of a novel digital therapeutics system on nonalcoholic steatohepatitis: the NASH App clinical trial

Management of nonalcoholic steatohepatitis (NASH) is a currently unmet clinical need. Digital therapeutics (DTx) is an emerging class of medicine that delivers evidence-based therapeutic interventions. The current study was aimed at investigating the efficacy of DTx in patients with NASH.METHODS: We conducted a multicenter, single-arm, 48-week trial in 20 patients with biopsy-confirmed NASH. All patients received …

Continue reading Impact of a novel digital therapeutics system on nonalcoholic steatohepatitis: the NASH App clinical trial

Non-heavy alcohol use associates with liver fibrosis and ‘nonalcoholic’ steatohepatitis in the Framingham Heart Study

Background and AimsWhile heavy alcohol use consistently associates with liver disease, the effects of non-heavy alcohol consumption are less understood. We aimed to investigate the relationship between non-heavy alcohol use and chronic liver disease.MethodsThis cross-sectional study included 2629 current drinkers in the Framingham Heart Study who completed alcohol use questionnaires and transient elastography. We defined …

Continue reading Non-heavy alcohol use associates with liver fibrosis and ‘nonalcoholic’ steatohepatitis in the Framingham Heart Study

MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis

Patients with NASH, NAS≥4, and F≥2 (Fibro-NASH) are at highest risk for disease progression.➢Patients with Fibro-NASH are targeted for proof-of-concept NASH trials.➢MRI-PDFF and MR elastography are the most common primary and secondary endpoints in NASH trials, respectively.➢To identify Fibro-NASH, the MRI-AST (MAST) score was created based on these MRI techniques.➢The MAST score was proven to …

Continue reading MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis

EDP-305 in patients with #NASH: A phase II double-blind placebo-controlled dose-ranging study

•EDP-305 is an oral farnesoid X receptor (FXR) agonist being developed to treat nonalcoholic steatohepatitis (NASH).•In a randomized, placebo-controlled study, 12-week study, EDP-305 reduced ALT levels and MRI-PDFF•These results support further development of EDP-305 in patients with NASH with longer term studies. ABSTRACTBackground & AimsEDP-305 is an oral farnesoid X receptor (FXR) agonist under development …

Continue reading EDP-305 in patients with #NASH: A phase II double-blind placebo-controlled dose-ranging study

XCR1+ type 1 conventional #dendritic cells drive liver pathology in non-alcoholic #steatohepatitis

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are prevalent liver conditions that underlie the development of life-threatening cirrhosis, liver failure and liver cancer. Chronic necro-inflammation is a critical factor in development of NASH, yet the cellular and molecular mechanisms of immune dysregulation in this disease are poorly understood. Here, using single-cell transcriptomic analysis, …

Continue reading XCR1+ type 1 conventional #dendritic cells drive liver pathology in non-alcoholic #steatohepatitis